Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are emerging as an exciting new class of agents for treating cancer. There is pre-clinical evidence for their use to potentiate both chemotherapeutic agents and radiotherapy, and also as single agents. This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.
1 Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. Mutat Res 1991;250:3–16.
2 Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511(2):145–78.
3 Hansen K, Kelly M. Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther 2000;295(1):1–9.
4 Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:360–74.
5 Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789–99.
6 Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005;31(8):603–17.
7 Bradbury PA, Middleton MR. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004;15(5):421–6.
8 Purnell MR, Whish WJD. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 1980;185:775–7.
9 Griffin RJ, Pemberton LC, Rhodes D, Bleasdale C, Bowman K, Calvert AH, et al. Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anticancer Drug Des 1995;10(6):507–14.
10 Curtin N. PARP inhibitors for cancer therapy. Expert reviews in molecular medicine 2005;7(4):1–20.
11 Southan G, Szabo C. Poly(ADP-ribose) ploymerase inhibitors. Curr Med Chem 2003;10:321–40.
12 Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998;78:1269–77.
13 Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995;72:849–56.
14 Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6(7):2860–7.
15 Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371–82.
16 Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9(14):5370–9.
17 Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005;4:1364–8.
18 Albert J, Cao C, Kim K, Willey C, Geng L, Xiao D, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13(10):3033–42.
19 Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6(3):945–56.
20 Durkacz B, Omidiji O, Gray D, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980;283:593–6.
21 Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35–61.
22 Tentori L, Graziani G, Gilberti S, Lacal PM, Bonmassar E, D'Atri S. Triazene compounds increase apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukaemic cell lines. Leukemia 1995;9:1888–95.
23 Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signalling induction of apoptosis by alkylating agents. Proc Natl Acad Sci U S A 1999;96:10764–9.
24 Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 1996;28:69–85.
25 D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54(2):334–41.
26 Fink D, Aebi S, Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1–6.
27 Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005;11:3402–9.
28 Plummer ER, Middleton MR, Wilson R, Evans J, Robson L, Steinfeldt H, et al. First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2005
29 Plummer ER, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006;24(18s):456s
30 Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005;36(7):724–31.
31 Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, et al. Hepatocellular carcinoma: treatment and recurrence marker. J Gastroenterol Hepatol 2001;16:338–44.
32 Hirai K, Ueda JC, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human cancer adenomatour polyps and cancers. Cancer Res 1983;43:3441–6.
33 Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434(7035):913–17.
34 Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917–21.
35 Fong P, Spicer J, Reade S, Reid A, Vidal L, Schellens J, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J Clin Oncol 2006;24(Suppl):3022
36 McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109–15.
37 Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139–48.
38 Turner N, Tutt A, Ashworth A. Hallmarks of BRCA-ness in sporadic cancer. Nat Rev Cancer 2004;4:814–19.